聯邦製藥(03933.HK)附屬成立獸用藥合資公司
聯邦製藥(03933.HK)公佈,全資附屬聯邦製藥(內蒙古)與浙江普洛共同簽署了獸用藥合作框架協議,聯邦製藥(內蒙古)與浙江普洛將以現金方式出資成立合資公司,註冊資金爲3億元人民幣(下同),聯邦製藥(內蒙古)將持有合資公司49%股權。
公司表示,合資公司前期合作項目涉及四個獸用抗生素產品。產品的生產管理由雙方各自負責,產品營銷由浙江普洛委派於合資公司的團隊負責。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.